# Knopp Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/knopp-biosciences

- Industry: Biotechnology
- Headquarters: Pittsburgh, US
- Website: www.knoppbio.com
- Total disclosed funding: $39M
- Latest round: Series C (Nov 11, 2020)
- Investors on record: 4

## About

Knopp Biosciences LLC is a biopharmaceutical company focused on developing innovative therapies for immunological and neurological diseases, particularly for eosinophilic asthma and epilepsy.Founded in 2005 and headquartered in Pittsburgh, US, Knopp Biosciences LLC specializes in the development of therapies targeting challenging health conditions. The company has undergone strategic pivots focusing on its lead product, dexpramipexole, after collaborations with other firms. In November 2020, it raised USD 5.04 mn in Series C funding led by Solas BioVentures, marking a significant step in its funding journey.Knopp Biosciences concentrates on innovative therapies for immunological and neurological diseases. Its primary product, dexpramipexole, is an oral small molecule under development for eosinophilic asthma, developed in partnership with Areteia Therapeutics, Inc. Additionally, the company's Kv7 platform, designed for epilepsy and other hyperexcitability disorders, has been acquired by Biohaven Pharmaceuticals for further development. Knopp’s solutions aim to meet unaddressed medical needs primarily in the U.S. market, which has a strong healthcare infrastructure and demand for advanced treatments.Revenue for Knopp Biosciences primarily arises from strategic partnerships with pharmaceutical firms and management of equity securities alongside future product royalties. Collaborations, such as with Areteia Therapeutics and Biohaven Pharmaceuticals, allow for milestone payments and royalties based on successful product commercialization. This model aids Knopp in minimizing financial risk while advancing its research and development capabilities, especially for clinical-stage products like dexpramipexole and the Kv7 platform.Knopp Biosciences plans to utilize the recent USD 5.04 mn funding from its Series C round to initiate a Phase 2 trial of oral dexpramipexole for moderate-to-severe eosinophilic asthma. Furthermore, the company is set to launch first-in-human studies of KB-3061 in 2021. The strategic focus includes expanding its market presence in new regions, ensuring alignment with healthcare demands, and leveraging funding for advancing its pipeline of therapies.

## Funding rounds

- Series C, Nov 11, 2020, $5M — Solas BioVentures
- Series C, Jun 30, 2020, $7.6M — Solas BioVentures
- Series B, Nov 19, 2008, $6.6M — Saturn Partners, Kramer Capital Partners
- Series B, Jan 22, 2008, $10M — Saturn Partners, Kramer Capital Partners, LaunchCyte
- Series A, Jan 1, 2006, $10M — Saturn Partners, Kramer Capital Partners, LaunchCyte

## Investors

- Saturn Partners (https://capitalatlas.ai/funds/saturn-partners) — Series A, Series B
- Kramer Capital Partners — Series A, Series B
- LaunchCyte (https://capitalatlas.ai/funds/launchcyte) — Series A, Series B
- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series C